Fennec Pharmaceuticals (FENC) Proxy filing summary

Executive summary

• Annual and special meeting scheduled for June 10, 2026, to be held virtually, with shareholders voting on key corporate matters including board elections, auditor appointment, executive compensation, and equity plans.

• Record date for voting is April 13, 2026, with 34,712,756 common shares outstanding, each carrying one vote.

• Board recommends voting in favor of all management proposals, including amendments to equity incentive plans and the adoption of a new inducement plan.

Voting matters and shareholder proposals

• Shareholders will vote to set the board size at five, elect five directors, appoint auditors, approve executive compensation, determine frequency of say-on-pay votes, amend the 2020 Equity Incentive Plan, and adopt the 2026 Equity Inducement Plan.

• Advisory votes on executive compensation and its frequency are included, with the board recommending annual say-on-pay votes.

• Shareholders may submit proposals for the next annual meeting by December 26, 2025.

Board of directors and corporate governance

• Board to be reduced from six to five members following the retirement of one director.

• Majority of directors are independent, with robust governance practices, including annual self-evaluations and a diversity policy.

• Board committees include Audit, Compensation, and Governance and Nominating, all with independent membership.

• Board and committees met regularly in 2025, with full attendance by directors.